Trans-Arterial Radioembolization with Yttrium-90 of Unresectable and Systemic Chemotherapy Resistant Hepatoblastoma in Three Toddlers.
Hüseyin Tuğsan BallıKairgeldy AikimbaevIsa Burak GuneyFerhat Can PiskinBegül Yağcı-KüpeliSerhan KupeliTuran KanmazPublished in: Cardiovascular and interventional radiology (2022)
The aim of this short communication was to report the results of transarterial radioembolization (TARE) with Yttrium-90 (Y90) loaded resin microspheres in three toddlers with unresectable and systemic chemotherapy-resistant HB hepatoblastoma (HB). Six TARE procedures were performed on the patients. The dose required for treatment was calculated using partition model. Administered doses of Y90 were 1.369, 0.851, and 1.147 GBq. Complete radiological response in two patients and partial response enabling liver resection in one patient were achieved. Neither life-threatening nor minor complications developed after the treatment. These results demonstrates that HB is a radiosensitive neoplasm, and TARE-Y90 can be used as the primary, neoadjuvant and palliative treatment method in patients with unresectable and systemic chemotherapy-resistant HBs. However, studies with higher number of patients and long-term results are required.
Keyphrases
- end stage renal disease
- locally advanced
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- liver metastases
- rectal cancer
- radiation therapy
- patient reported outcomes
- combination therapy
- high resolution
- mass spectrometry
- cancer therapy
- replacement therapy
- drug induced
- radiofrequency ablation
- case control